Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial

M. Packer*, S.D. Anker, J. Butler, G. Filippatos, J.P. Ferreira, S.J. Pocock, H.P. Brunner-La Rocca, S. Janssens, H. Tsutsui, J. Zhang, M. Brueckmann, W. Jamal, D. Cotton, T. Iwata, J. Schnee, F. Zannad, EMPEROR‐Reduced Trial Committees and Investigators

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

15 Citations (Web of Science)
Original languageEnglish
Pages (from-to)671-680
Number of pages10
JournalEuropean Heart Journal
Volume42
Issue number6
DOIs
Publication statusPublished - 7 Feb 2021

Keywords

  • Heart failure
  • Empagliflozin
  • Sacubitril/valsartan

Cite this